image credit: Pixabay

Pfizer’s immunology ambitions delayed—again—as JAK drugs fall victim to FDA’s protracted safety review

July 22, 2021


Pfizer and its JAK inhibitors are falling deeper down a regulatory rabbit hole the company itself opened up.

The FDA has once again pushed back two decisions key to Pfizer’s immunology franchise: Xeljanz in ankylosing spondylitis and abrocitinib in atopic dermatitis, the New York pharma said Wednesday.

The latest delay came on top of an initial holdup Pfizer unveiled in April, when the FDA extended those reviews by three months. This time, Pfizer didn’t say whether the FDA had set new deadlines.

Read More on FiercePharma